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Introduction
Angiotensin-converting enzyme (ACE) is a dipeptidyl-dipeptidase capable of cleaving the decapeptide angiotensin I to produce the potent, pressor octapeptide angiotensin II (Soffer, 1976) . Captopril is an orally active and relatively specific inhibitor of ACE, as well as an effective antihypertensive agent in man and other animals (Heel, Brogden, Speight & Avery, 1980; Cushman, Cheung, Sabo & Ondetti, 1981) .
While the hypotensive action of captopril is believed to be secondary to the blockade of ACE (Antonaccio, Rubin & Horovitz, 1980) , the precise mechanism is unclear. Captopril has been shown to lower blood pressure of spontaneously hypertensive (SH) rats by a mechanism that is apparently independent of both the renal and vascular wall reninangiotensin system (Hutchinson & Mendelsohn, 1980) . The finding that both bradykinin (Dorer, Kahn, Lentz, Levine & Skeggs, 1974) and enkephalin (Erdos, Johnson & Boyden, 1978) are substrates for ACE raises the possibility that potentiation of either of these peptides by captopril could be involved in the acute hypotensive action of captopril in the anaesthetized SH rat. However, despite the finding that captopril increases the level of circulating kinins in experimental animals (McCaa, Hall & McCaa, 1978; Matthews & Johnston, 1979) , bradykinin is not believed to play a major role in the hypotensive action of captopril in animals (see review Antonaccio et al., 1980) or man (Millar & Johnston, 1979) . The role of endogenous opioids in the hypotensive action of captopril has not yet been examined; however, the finding that captopril potentiates morphine-induced respiratory depression (Oktay, Onur, Mustafa & Turker, 1981) and analgesia (Ercan, Ilhan & Turker, 1980) suggests that ACE is involved in the metabolism of endogenous opiates and that captopril treatment may result in the accumulation of endogenous opioids.
Intravenous administration of the opioid peptide, methionine-enkephalin (Met-enkephalin) to the anaesthetized cat (Moore & Dowling, 1980) and rat (Wei, Lee & Chang, 1980) results in a rapid, transient fall in blood pressure. Given that the degradation of systemic enkephalin is believed to be by the action of a dipeptidyl dipeptidase associated with vascular endothelial tissue (Erdos et al., 1978; Benuck & Marks, 1979) were given (10, 20, 40, and 80 tig kg-I each in 0.1 ml) in a randomized manner at 10 min intervals. Each animal then received either captopril (2 mg kg-1, i.v.) or saline (0.1 ml, i.v.) and the doses of Metenkephalin were repeated. In a further group of rats, the effect of naloxone (1.5 mgkg 1, i.v.) on the response to a 40 jig kg-' dose of Met-enkephalin was studied over a 3 h period.
Experiment 2: The protocol of Experiment 1 was followed except that nitroprusside (Roche) was given in 3 doses (2.5, 5 and lOiggkg-1) instead of the 4 doses of Met-enkephalin.
Experiment 3: spontaneously hypertensive (SH) rats of the Okamoto strain (250-300g) were prepared as above and 1 h after surgery they received either naloxone (1.5 mg kg-1, i.v.) or vehicle (0.1 ml of 0.9% saline, i.v.). After a further 30 min each rat received a bolus injection of captopril (2 mg kg-1, i.v.). Blood pressure was monitored continuously until 3 h after captopril had been given. Two way analysis of variance (Armitage, 1977) (193 ± 4 to 171 ± 6 mmHg).
Discussion
In the present study captopril significantly potentiated the vasodepressor action of Met-enkephalin in anaesthetized rats. The altered responses to Metenkephalin following captopril were not due to changes either in tissue sensitivity or in experimental protocol as captopril failed to alter the vasodepressor responses to the non-specific vasodilator, nitroprusside.
Since Met-enkephalin is a substrate for dipeptidyl dipeptidase (Erdos et al., 1978) , captopril may potentiate the action of circulating Met-enkephalin by the blockade of this enzyme. Captopril induces respiratory depression (Oktay et al., 1981) and analgesia (Ercan et al., 1980) in mice, effects which could occur by potentiation of endogenous opioids. The facts that Met-enkephalin is vasodepressor in the anaesthetized rat (Wei etal., 1980) and that its action is augmented by captopril suggest that potentiation of endogenous opioids by captopril may contribute to its own hypotensive action in anaesthetized SH rats. However naloxone, at a dose known to antagonize powerfully the vasodepressor action of Metenkephalin (Table 1) , failed to alter significantly the hypertensive action of captopril in anaesthetized SH rats. Thus, it seems unlikely that potentiation of endogenous opioids contributes to the hypotensive action of captopril in these animals.
While captopril is a potent inhibitor of ACE and Met-enkephalin is a substrate for purified ACE, it is not known whether the effects of captopril on the actions of Met-enkephalin seen in this study were due to the inhibition of ACE and/or some other 'enkephalinase'. There is some evidence to suggest that, in some tissues, there exists an 'enkephalinase' that is distinct from ACE (Swerts, Perdrisot, Patey, De La Baume & Schwartz, 1979) .
While intravenous Met-enkephalin decreases blood pressure in the anaesthetized rat (Wei et al., 1980) and cat (Moore & Dowling, 1980) in the conscious rat, Met-enkephalin causes an increase in blood pressure (Simon, Schaz, Ganten, Stock, Schlor & Ganten, 1978) . Thus, potentiation of this opioid by captopril is unlikely to be involved in the hypotensive action of captopril in the conscious SH rat. Nevertheless similar studies to the present ones are warranted in conscious animals.
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